Jean-Guillaume Lafay, Mablink Bioscience CEO
A French biotech nabs Series A to see if it can carve a role in the ADC space
Nobody wanted the patent.
University of Lyon researchers had developed a hydrophilic drug-linker platform for antibody-drug conjugates, now a hot field thanks to the likes …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
